LungArchives
The impact of comorbidities on the all-cause mortality of surgically treated non-small cell lung cancer patients - visualization with the aid of a comorbidome
Lung 6 min.
In 2020 lung cancer was the second most common cancer and the leading cause for cancer death [1]. Surgery, if possible, is known as the first choice of treatment. Lobectomy or segmentectomy are the standard procedures for anatomical resection. They are mainly performed by video-assisted thoracoscopic...
Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus
Lung 1 min.
Lung cancer is the leading cause of cancer-related death and the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. In the Middle East and North Africa (MENA) region, lung cancer ranks second in incidence and cancer mortality,...
Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
Lung 1 min.
The first-line treatment landscape for patients with NSCLC harboring sensitizing EGFRmutations is rapidly evolving. Initially, osimertinib was the one and only option over earlier generation EGFR inhibitors based on the positive PFS and OS results from the FLAURA study. This paper reviews and...
Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer
Lung 8 min.
According to the 2020 GLOBOCAN report, lung cancer is the second most commonly diagnosed cancer worldwide, accounting for 11.4% of new cases, and it has the highest mortality rate, responsible for 18% of cancer-related deaths [1]. Non-small cell lung cancer (NSCLC) represents approximately 85% of these...
